ArticleCureus2025
Catecholamine-Secreting Non-small Cell Lung Cancer Presenting With Hypertensive Crisis: A Report of a Rare Case.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ectopic catecholamine production by non-small cell lung cancer (NSCLC) is exceptionally rare and, to our knowledge, has not been previously reported in the literature. We present the case of a 68-year-old woman with advanced lung adenocarcinoma who presented in hypertensive crisis due to markedly elevated normetanephrine levels. Initial suspicion was for pheochromocytoma, but normal chromogranin A levels suggested a paraneoplastic phenomenon. Despite alpha-adrenergic blockade, the patient's metastatic disease and refractory hypertension contributed to poor treatment tolerance, ultimately necessitating transition to hospice care. This case underscores the importance of considering atypical endocrine manifestations of NSCLC and highlights the challenges of managing advanced cancer complicated by paraneoplastic syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.